Pro Medicus Limited (ASX:PME): 2026 Visage 7 Contracts Extend Enterprise Imaging Footprint

Sonal Goyal

07 October 2026 12:01 AM AEDT

Pro Medicus Limited (ASX:PME): 2026 Visage 7 Contracts Extend Enterprise Imaging Footprint

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus signed multiple 2026 agreements for its Visage 7 enterprise imaging platform across US health systems.
A five-year A$37M renewal with Northwestern Medicine included higher minimum commitments and a higher fee per transaction.
The company signed a five-year A$23M agreement with the University of Maryland Medical System for cloud-based Visage 7 Viewer and Workflow.
TidalHealth selected a seven-year A$16M cloud deployment covering the Visage 7 full stack plus Cardiology Imaging.
Contract structures remained transaction-based, linking Revenue to imaging volumes and agreed commercial terms.

Pro Medicus Limited (ASX:PME) is a healthcare informatics company that develops and supplies medical imaging software and services to hospitals, imaging centres and healthcare groups worldwide. Its Visage 7 platform supports enterprise imaging in public and private cloud environments. During 2026, the company expanded its contracted customer base and renewed existing relationships through a series of multi-year agreements, highlighting continued adoption of its cloud-based imaging architecture across large US healthcare organisations.

Contract Renewals Reinforce Existing Customer Relationships

One of the most notable 2026 renewals was announced on 13 April, when Pro Medicus confirmed a five-year A$37M renewal with Northwestern Medicine for Visage 7 Viewer. The renewal was negotiated with higher minimum commitments and an increased fee per transaction. Management said the revised minimums reflected growth in examination volumes since Northwestern Medicine standardised on the platform five years earlier.

That agreement followed two five-year renewals announced on 9 March with a combined minimum value of A$40M. The contracts included a A$31M renewal with MedStar Health for the Visage 7 suite, with Cardiology Imaging added, and a A$9M Viewer renewal with Zwanger-Pesiri. Both were structured on a transaction-based model and included increased per-transaction fees.

New Health System Agreements Broaden Cloud Deployment

Pro Medicus also secured new customer agreements during 2026. On 8 April, the company announced a five-year A$23M contract with the University of Maryland Medical System. The agreement covers Visage 7 Viewer and Visage 7 Workflow and is planned as a cloud implementation. The rollout was scheduled to begin immediately, with go-live targeted for early calendar 2027.

On 1 June, Pro Medicus announced a seven-year A$16M contract with TidalHealth. The agreement includes Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive and Visage 7 Cardiology Imaging. The system is also planned for cloud deployment, with go-live targeted for the first quarter of calendar 2027. The inclusion of cardiology broadens the use of the platform beyond radiology workflows within the customer environment.

Transaction-Based Model Remains Central

The 2026 agreements continue Pro Medicus' established transaction-based licensing approach. Under this model, contract value is linked to agreed minimums and imaging activity rather than a fixed software licence alone. Several 2026 announcements also noted potential additional revenue if transaction volumes exceed contracted minimum levels. This structure means customer examination volumes and implementation progress remain important operating measures in assessing contract performance.

The company's cloud deployment strategy is also a recurring feature of its 2026 contracts. Visage 7 is designed as a scalable enterprise imaging platform, and the agreements with the University of Maryland Medical System and TidalHealth both specify cloud-based implementation. The product mix across these deals spans Viewer, Workflow, Open Archive and Cardiology Imaging, showing how customer deployments can involve different combinations of modules.

Key Insights

Pro Medicus' 2026 disclosures show a combination of new enterprise customer wins and renewals with existing health systems. The renewal activity indicates continued use of Visage 7 by established customers, while new contracts extend the platform into additional hospital networks. The principal factors for readers to follow are implementation timing, contracted transaction volumes, customer renewals and the adoption of additional Visage 7 modules across enterprise imaging environments.

FAQs

Q: What does Pro Medicus Limited do?

A:Pro Medicus develops and supplies medical imaging software and services, including the Visage 7 enterprise imaging platform.

Q: What was the value of the 2026 Northwestern Medicine renewal?

A:The five-year renewal announced on 13 April 2026 had a minimum value of A$37M.

Q: Which Visage 7 modules did TidalHealth select?

A:TidalHealth selected Viewer, Workflow, Open Archive and Cardiology Imaging under a seven-year A$16M contract.

Q: How are many Pro Medicus contracts structured?

A:The 2026 agreements cited by the company use transaction-based licensing models with agreed minimum commitments and potential additional revenue from higher transaction volumes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.